
WisdomTree International Quality Dividend Growth Fund (IQDG) Price & Chart
IQDG ETF Chart & Stats
- Day’s Range
- $42.11 - $42.45
- 52-Week Range
- $38.64 - $44.98
- Previous Close
- $42.41
- Volume
- 20.91K
- Average Volume (3M)
- 36.38K
- AUM
- 686.99M
- NAV
- 42.20
- Expense Ratio
- 0.42%
- Holdings Count
- 277
- Beta
- 0.83
- Inception Date
- Apr 07, 2016
- Last Dividend Ex-Date
- Sep 25, 2026
- Dividend Yield
- (2.40%)
- Shares Outstanding
- 16,200,000
- Standard Deviation
- N/A
ETF Overview
WisdomTree International Quality Dividend Growth Fund
The WisdomTree International Quality Dividend Growth Fund, trading under the ticker IQDG, is a distinctive exchange-traded fund (ETF) that offers investors exposure to a carefully curated selection of international companies distinguished by their superior dividend growth potential and quality metrics. Positioned within the Total Market category, this ETF provides a comprehensive approach to capturing investment opportunities across a wide array of market capitalizations and styles. However, its true niche lies in its Broad-based focus, which emphasizes the selection of global equities that not only demonstrate strong financial health but also possess the capacity to sustain and increase dividends over time. IQDG is crafted for investors seeking to diversify their portfolios with international equities that combine the appeal of dividend income with the robust growth characteristics of high-quality companies. By targeting firms with solid earnings, healthy balance sheets, and a proven track record of dividend growth, the fund aims to deliver a compelling investment proposition. This focus on quality and growth in the international arena makes IQDG an attractive option for those looking to enhance their returns while managing risk through global diversification.
- Asset Class
- Equity
- Region
- Developed Markets
- Issuer
- WisdomTree
- Index Tracked
- WisdomTree International Quality Dividend Growth Index
- Ticker Symbol
- IQDG
IQDG ETF News


AstraZeneca plc ($GB:AZN) announced an update on their ongoing clinical study. Study Overview: AstraZeneca’s official study title is Breast Cancer Real-World Insights and Decision Guidance Evaluation (BRIDGE-HK) An Observational, Retrospective,

AstraZeneca plc ($GB:AZN) announced an update on their ongoing clinical study. Study Overview: AstraZeneca’s NCT07685600 study, officially titled “An Open-label, Randomised, Two Arm, Fixed Sequence Study in Healthy Participants to

IQDG ETF FAQ
What was IQDG’s price range in the past 12 months?
What is the AUM of IQDG?
Is IQDG overvalued?
Does IQDG pay dividends?
How many shares outstanding does IQDG have?
Top 10 Holdings
| Name | Weight % |
|---|---|
| NOVNNovartis | 3.39% |
| ROPRoche Holding | 3.37% |
| 7203Toyota Motor Corp (UK) | 2.89% |
| AZNAstraZeneca plc | 2.88% |
| NOVO.BDK:NOVO.B | 2.83% |
| ASMLASML Holding NV | 2.76% |
| ORL'Oreal S.A. (UK) | 2.51% |
| ITXINDUSTRIA DE DISENO TEXTIL | 2.49% |
| MCLVMH Moet Hennessy Louis Vuitton (UK) | 2.49% |
| BBVABanco Bilbao Vizcaya Argentaria SA | 2.45% |
| Total | 28.06% |










